Genomic Health Inc (GHDX)

30.01
NASDAQ : Health Care
Prev Close 29.57
Day Low/High 29.20 / 30.29
52 Wk Low/High 22.00 / 35.79
Avg Volume 195.30K
Exchange NASDAQ
Shares Outstanding 33.48M
Market Cap 989.98M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX® Prostate Cancer Test Predicts Risk Of Metastasis And Mortality

Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX® Prostate Cancer Test Predicts Risk Of Metastasis And Mortality

Oncotype DX® Genomic Prostate Score™ Becomes Only Test Validated to Measure All Four Critical Features of Tumor Aggressiveness

Comprehensive Economic Analysis Published In Reviews In Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads To Substantial Cost Savings And Increase In Active Surveillance

Comprehensive Economic Analysis Published In Reviews In Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads To Substantial Cost Savings And Increase In Active Surveillance

Unique Prospective Study Provides Real-world Evidence Demonstrating Use of Oncotype DX® Genomic Prostate Score™ Saves Over $2,000 per Patient by Optimizing Care and Healthcare Spending

Genomic Health Presents Robust Analytical Validation Study Results Of Oncotype SEQ™ Liquid Biopsy Mutation Panel

Genomic Health Presents Robust Analytical Validation Study Results Of Oncotype SEQ™ Liquid Biopsy Mutation Panel

Data Presented for First Time at ESMO 2016 Congress Highlight Company's Commitment to Delivering Rigorous, Clinically Actionable Liquid-based Tests for Late-stage Cancer Patients

Multiple Oncotype DX® Presentations At ESMO 2016 Congress Reinforce Its Unique Clinical Utility With Prospective Outcomes Results In Over 63,000 Breast Cancer Patients

Multiple Oncotype DX® Presentations At ESMO 2016 Congress Reinforce Its Unique Clinical Utility With Prospective Outcomes Results In Over 63,000 Breast Cancer Patients

Two Large International Studies Underscore Ability of Oncotype DX to Identify Patients with Node-positive Breast Cancer Who Can Forego Chemotherapy and Its Side Effects

Genomic Health Reinforces Global Leadership In Genomic-based Diagnostics With Presentation Of Nine Personalized Medicine Studies Conducted In Six Countries At ESMO 2016 Congress

Genomic Health Reinforces Global Leadership In Genomic-based Diagnostics With Presentation Of Nine Personalized Medicine Studies Conducted In Six Countries At ESMO 2016 Congress

Broad Range of Presentations Includes Oncotype SEQ™ Liquid Biopsy Analytical Validation, New Outcomes Data in Invasive Breast Cancer and Studies in Node-positive Disease

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

These five stocks could be toxic for your portfolio in the month ahead.

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Investors considering a purchase of Genomic Health Inc stock, but cautious about paying the going market price of $26.70/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $22.50 strike, which has a bid at the time of this writing of $1.25.

Genomic Health (GHDX): Today's Weak On High Volume Stock

Genomic Health (GHDX): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Genomic Health (GHDX) as a weak on high relative volume candidate

Genomic Health And Epic Sciences Announce Strategic Collaboration To Deliver Novel AR-V7 Liquid Biopsy Test To Predict Treatment Response In Metastatic Prostate Cancer

Genomic Health And Epic Sciences Announce Strategic Collaboration To Deliver Novel AR-V7 Liquid Biopsy Test To Predict Treatment Response In Metastatic Prostate Cancer

Validation Study Led by Memorial Sloan Kettering Cancer Center, Published in JAMA Oncology, Demonstrated Patients with AR-V7 Positive Circulating Tumor Cells Have Significantly Better Outcomes if Treated with Chemotherapy versus Hormonal Treatments

Genomic Health Launches Oncotype SEQ™ Liquid Biopsy Mutation Panel

Genomic Health Launches Oncotype SEQ™ Liquid Biopsy Mutation Panel

Genomic Health Provides Unique New Option for Non-invasive Tumor Assessment in Later-stage Disease, Transforming Cancer Care Across the Patient Journey

Nature Partner Journals Publish Five-year Outcomes Results From SEER Registry Demonstrating Oncotype DX® Accurately Identifies Early-stage Breast Cancer Patients With Excellent Survival

Nature Partner Journals Publish Five-year Outcomes Results From SEER Registry Demonstrating Oncotype DX® Accurately Identifies Early-stage Breast Cancer Patients With Excellent Survival

Study Showed Node-negative and Node-positive Patients with Low Oncotype DX® Breast Recurrence Score™ Results - the Vast Majority Treated without Chemotherapy - Had Excellent Breast Cancer Survival

Genomic Health Announces Multiple Oncotype DX® Presentations At ASCO 2016 Showcasing Industry-leading Commitment To Bringing Precision Medicine To Cancer Patients

Genomic Health Announces Multiple Oncotype DX® Presentations At ASCO 2016 Showcasing Industry-leading Commitment To Bringing Precision Medicine To Cancer Patients

Four New Analyses of SEER Registry Provide Additional Evidence that Oncotype DX Accurately Predicts Patient Outcomes in Node-negative and Node-positive Breast Cancer and Reinforce Its Value in Older Women

Genomic Health Announces Presentation Of Seven Oncotype DX® Studies At The 2016 American Society Of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis

Genomic Health Announces Presentation Of Seven Oncotype DX® Studies At The 2016 American Society Of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis

Presentations in Breast and Prostate Cancers Underscore Genomic Health's Industry-leading Commitment to Help Physicians and Patients Optimize Cancer Treatment Decisions

Genomic Health Announces Publication In Journal Of Clinical Oncology Demonstrating Oncotype DX® Predicts Late Distant Recurrence In Breast Cancer

Genomic Health Announces Publication In Journal Of Clinical Oncology Demonstrating Oncotype DX® Predicts Late Distant Recurrence In Breast Cancer

Findings Confirm that Oncotype DX May Help Identify Breast Cancer Patients with Greatest Potential to Benefit from Extended Hormonal Therapy

Genomic Health (GHDX) Strong On High Relative Volume Today

Genomic Health (GHDX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Genomic Health (GHDX) as a strong on high relative volume candidate

Today's Weak On High Volume Stock: Genomic Health (GHDX)

Today's Weak On High Volume Stock: Genomic Health (GHDX)

Trade-Ideas LLC identified Genomic Health (GHDX) as a weak on high relative volume candidate

Commit To Purchase Genomic Health At $17.50, Earn 6.4% Annualized Using Options

Commit To Purchase Genomic Health At $17.50, Earn 6.4% Annualized Using Options

Investors eyeing a purchase of Genomic Health Inc shares, but tentative about paying the going market price of $23.58/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $17.50 strike, which has a bid at the time of this writing of 55 cents.

Genomic Health Announces Five-year Outcomes From International 'PlanB' Study Demonstrating The Clinical Utility Of Oncotype DX® In Node-positive And High-risk Node-negative Breast Cancer

Genomic Health Announces Five-year Outcomes From International 'PlanB' Study Demonstrating The Clinical Utility Of Oncotype DX® In Node-positive And High-risk Node-negative Breast Cancer

One of the Largest Contemporary Adjuvant Breast Cancer Trials in Europe Shows that Patients with Low Oncotype DX® Scores Can Be Spared Chemotherapy Even When Traditional Factors Indicate Higher-Risk Disease

German National Cancer Guidelines Distinguish Oncotype DX® As First And Only Multi-gene Breast Cancer Test With 1A Level Of Evidence

German National Cancer Guidelines Distinguish Oncotype DX® As First And Only Multi-gene Breast Cancer Test With 1A Level Of Evidence

Updated Guidelines Elevate Evidence following Publication of Multiple Large Prospective Outcomes Studies

Journal Of Clinical Oncology Publishes Prospective Outcomes Results From Large International Trial Using Oncotype DX®

Journal Of Clinical Oncology Publishes Prospective Outcomes Results From Large International Trial Using Oncotype DX®

New Publication of Results from 'PlanB' Study Reinforces Unique Value of Oncotype DX, the Only Multi-gene Breast Cancer Test with Prospective Outcomes Evidence in More Than 50,000 Patients